Log in

NYSE:TAKTakeda Pharmaceutical News Headlines

$14.59
-0.14 (-0.95 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.46
Now: $14.59
$14.71
50-Day Range
$13.02
MA: $16.71
$20.09
52-Week Range
$12.43
Now: $14.59
$20.92
Volume963,646 shs
Average Volume2.45 million shs
Market Capitalization$46.00 billion
P/E Ratio56.12
Dividend Yield4.07%
Beta0.92

Headlines

Takeda Pharmaceutical (NYSE TAK) News Headlines

Source:
DateHeadline
Gout Therapeutics Market Technological Trends in 2020-2029 | Takeda Pharmaceutical Company, Novartis, AstraZenecaGout Therapeutics Market Technological Trends in 2020-2029 | Takeda Pharmaceutical Company, Novartis, AstraZeneca
www.marketwatch.com - April 1 at 7:36 AM
Singapore Pharmaceutical Market Outlook 2017-2030 - by Goldstein Market IntelligenceSingapore Pharmaceutical Market Outlook 2017-2030 - by Goldstein Market Intelligence
www.marketwatch.com - March 31 at 4:34 PM
Takeda Pharma Reports Positive CHMP Opinion For ADCETRIS - Quick FactsTakeda Pharma Reports Positive CHMP Opinion For ADCETRIS - Quick Facts
www.nasdaq.com - March 31 at 11:33 AM
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell LymphomaTakeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
finance.yahoo.com - March 31 at 11:33 AM
Takeda Pharmaceutical Co Ltd (NYSE:TAK) Receives Consensus Rating of "Hold" from BrokeragesTakeda Pharmaceutical Co Ltd (NYSE:TAK) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 30 at 8:46 PM
Global Intravenous IV Iron Drugs Market 2020 – Sanofi US, Allergan, AMAG Pharmaceuticals, Dalichi SankyoGlobal Intravenous IV Iron Drugs Market 2020 – Sanofi US, Allergan, AMAG Pharmaceuticals, Dalichi Sankyo
www.marketwatch.com - March 30 at 6:45 AM
Evox Therapeutics and Takeda Sign Multi-target Rare Disease CollaborationEvox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration
www.prnewswire.com - March 26 at 1:58 PM
Drugmaker Takeda gives more than $6M to COVID-19 relief effortsDrugmaker Takeda gives more than $6M to COVID-19 relief efforts
finance.yahoo.com - March 25 at 4:34 PM
EU regulators to probe Johnson & Johnsons Takeda dealEU regulators to probe Johnson & Johnson's Takeda deal
www.reuters.com - March 25 at 11:33 AM
EU regulators to probe Johnson & Johnson's Takeda dealEU regulators to probe Johnson & Johnson's Takeda deal
finance.yahoo.com - March 25 at 11:33 AM
Exelixis Announces Partner Takeda Receives...Exelixis Announces Partner Takeda Receives...
www.benzinga.com - March 25 at 6:33 AM
Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic DisordersCodexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders
www.benzinga.com - March 23 at 7:54 AM
Codexis inks deal with Takeda to advance gene therapies for rare genetic disordersCodexis inks deal with Takeda to advance gene therapies for rare genetic disorders
seekingalpha.com - March 23 at 7:54 AM
Takeda Eyes Plasma Therapy for Covid-19 PatientsTakeda Eyes Plasma Therapy for Covid-19 Patients
finance.yahoo.com - March 22 at 1:24 PM
Stress Relief Supplements Market Fabulous Growth with Reputable Key Players- Interhealth, Alkermes, Ion Labs, Pfizer, TakedaStress Relief Supplements Market Fabulous Growth with Reputable Key Players- Interhealth, Alkermes, Ion Labs, Pfizer, Takeda
www.marketwatch.com - March 20 at 2:15 PM
Stock Traders Buy High Volume of Call Options on Takeda Pharmaceutical (NYSE:TAK)Stock Traders Buy High Volume of Call Options on Takeda Pharmaceutical (NYSE:TAK)
www.americanbankingnews.com - March 19 at 5:35 PM
The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidateThe Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate
finance.yahoo.com - March 17 at 10:59 PM
Drugmaker Takeda Sees Speedy Approval of Coronavirus TreatmentDrugmaker Takeda Sees Speedy Approval of Coronavirus Treatment
www.bloomberg.com - March 17 at 7:58 AM
8 Best Pharmaceutical Stocks to Buy for Income8 Best Pharmaceutical Stocks to Buy for Income
finance.yahoo.com - March 14 at 5:52 PM
JPMorgan Chase & Co. Lowers Takeda Pharmaceutical (NYSE:TAK) Price Target to $30.00JPMorgan Chase & Co. Lowers Takeda Pharmaceutical (NYSE:TAK) Price Target to $30.00
www.americanbankingnews.com - March 11 at 1:15 PM
Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call TranscriptSunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 9:47 PM
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Recent HighlightsSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights
www.marketwatch.com - March 10 at 4:46 PM
Takeda Provides Update on TOURMALINE-MM2 Phase 3 TrialTakeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
www.businesswire.com - March 10 at 11:46 AM
Takedas Ninlaro shows less-than-expected effect in first-line multiple myelomaTakeda's Ninlaro shows less-than-expected effect in first-line multiple myeloma
seekingalpha.com - March 10 at 11:46 AM
Dengue Fever Market to Witness Massive Growth by 2025 | Sanofi, Takeda Pharmaceutical, GlaxoSmithKlineDengue Fever Market to Witness Massive Growth by 2025 | Sanofi, Takeda Pharmaceutical, GlaxoSmithKline
www.marketwatch.com - March 6 at 1:05 PM
Takeda says its developing a plasma derived-therapy to treat coronavirus patientsTakeda says it's developing a plasma derived-therapy to treat coronavirus patients
www.cnbc.com - March 6 at 8:04 AM
Takeda, with US headquarters in Cambridge, says it’s working on a coronavirus treatmentTakeda, with US headquarters in Cambridge, says it’s working on a coronavirus treatment
www.msn.com - March 5 at 3:50 PM
Takeda launches development of coronavirus drugTakeda launches development of coronavirus drug
seekingalpha.com - March 5 at 10:50 AM
Takeda Pharmaceutical Announces a Plasma-Derived Coronavirus TherapyTakeda Pharmaceutical Announces a Plasma-Derived Coronavirus Therapy
www.fool.com - March 4 at 6:33 PM
BRIEF-Takeda Initiates Development Of A Plasma-Derived Therapy For Covid-19BRIEF-Takeda Initiates Development Of A Plasma-Derived Therapy For Covid-19
www.reuters.com - March 4 at 1:33 PM
Alnylam unveils coronavirus drug plans: 'We've learned our lesson' from SARSAlnylam unveils coronavirus drug plans: 'We've learned our lesson' from SARS
finance.yahoo.com - March 4 at 1:33 PM
Takeda completes asset sale to StadaTakeda completes asset sale to Stada
seekingalpha.com - March 4 at 8:33 AM
Japan’s Takeda Developing Coronavirus Drug, Dow Jones ReportsJapan’s Takeda Developing Coronavirus Drug, Dow Jones Reports
www.msn.com - March 4 at 8:33 AM
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics CompaniesThe Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
www.msn.com - March 4 at 8:33 AM
Takedas stock is up 6% as it details plans for a COVID-19 treatmentTakeda's stock is up 6% as it details plans for a COVID-19 treatment
www.marketwatch.com - March 4 at 8:33 AM
Takeda working on coronavirus drug, says to make announcement on WednesdayTakeda working on coronavirus drug, says to make announcement on Wednesday
www.reuters.com - March 4 at 8:33 AM
Drugmaker Takeda Is Working on Coronavirus DrugDrugmaker Takeda Is Working on Coronavirus Drug
www.wsj.com - March 4 at 8:33 AM
Takeda's stock is up 6% as it details plans for a COVID-19 treatmentTakeda's stock is up 6% as it details plans for a COVID-19 treatment
finance.yahoo.com - March 4 at 8:32 AM
Takeda to divest certain Latin American assets for $825MTakeda to divest certain Latin American assets for $825M
seekingalpha.com - March 2 at 12:44 PM
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung CancerTakeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
finance.yahoo.com - March 2 at 12:44 PM
Brazils Hypera Pharma to acquire pharma products from Japans Takeda for $825 millionBrazil's Hypera Pharma to acquire pharma products from Japan's Takeda for $825 million
www.nasdaq.com - March 2 at 7:44 AM
Takeda To Divest Select Products To Brazils Hypera For $825 Mln - Quick FactsTakeda To Divest Select Products To Brazil's Hypera For $825 Mln - Quick Facts
www.nasdaq.com - March 2 at 7:44 AM
Takeda, Merck invest in Waltham cancer startups $100M roundTakeda, Merck invest in Waltham cancer startup's $100M round
www.bizjournals.com - March 2 at 7:44 AM
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USDTakeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
finance.yahoo.com - March 2 at 7:44 AM
Takeda Completes Sale of Select OTC and Non-Core Assets to AcinoTakeda Completes Sale of Select OTC and Non-Core Assets to Acino
finance.yahoo.com - March 2 at 7:44 AM
Takeda, Merck invest in Waltham cancer startup's $100M roundTakeda, Merck invest in Waltham cancer startup's $100M round
finance.yahoo.com - March 2 at 7:44 AM
Horizon Therapeutics Closes $115 Million Deal For Takeda CampusHorizon Therapeutics Closes $115 Million Deal For Takeda Campus
www.msn.com - February 28 at 7:54 PM
Takeda sues Sun Pharma to halt copies of cancer drugTakeda sues Sun Pharma to halt copies of cancer drug
seekingalpha.com - February 28 at 2:54 PM
Takeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP OpinionTakeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP Opinion
www.nasdaq.com - February 28 at 8:39 AM
Takeda gets positive CHMP opinion for subcutaneous vedolizumabTakeda gets positive CHMP opinion for subcutaneous vedolizumab
seekingalpha.com - February 28 at 8:39 AM
This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel